NeuroThera Labs Expands Phase IIb Tourette Syndrome Trial to Yale Child Study Center

NeuroThera Labs Inc., a clinical-stage biotech company and majority-owned subsidiary of SciSparc Ltd., has launched its Phase IIb clinical trial site at the Yale Child Study Center, Yale School of Medicine, in New Haven, Connecticut. The study, led by Dr. Michael H. Bloch, will evaluate SCI-110, the company's proprietary cannabinoid-based drug candidate for the treatment of Tourette Syndrome (TS) in adults.

SCI-110 combines dronabinol with palmitoylethanolamide, an endocannabinoid-like compound, in a single dosage form designed to reduce tics and associated comorbid symptoms while minimizing side effects. The trial is also underway at Hannover Medical School in Germany and Tel Aviv Sourasky Medical Center in Israel, making this a global development program.

The initiation of the U.S. site is a significant milestone, according to Dr. Adi Zuloff-Shani, Chief Technology Officer of NeuroThera. TS remains a major unmet medical need, particularly in adults who suffer from persistent and debilitating symptoms. Current treatment options are limited, and SCI-110 has the potential to offer a more effective and safer approach. The company is committed to advancing this therapy and generating data to support regulatory approval.

The Phase IIb trial builds on positive results from the Phase IIa study, which showed an average tic reduction of 21% as measured by the Yale Global Tic Severity Scale Total Tic Score. The new trial is a randomized, double-blind, placebo-controlled, cross-over study. Patients aged 18-65 will be randomized to receive either SCI-110 or placebo, with the primary endpoint being the change in tic severity at weeks 12 and 26 compared to baseline. Safety will be monitored through adverse event assessments.

This expansion into a leading U.S. academic center underscores the potential of SCI-110 to address a condition with limited therapeutic options. The collaboration with Yale, known for its expertise in TS research, could accelerate the development of this novel treatment. If successful, SCI-110 could provide a new option for adults with TS who have not responded to existing therapies.

NeuroThera Labs focuses on developing novel therapeutics for central nervous system disorders and other underserved health conditions. The company's innovative combination approach may offer advantages over current treatments, which often have significant side effects or limited efficacy.

The trial's progress is closely watched by the medical community, given the high unmet need in TS. With the addition of the Yale site, the study is well-positioned to enroll participants and generate robust data. The outcomes could have implications not only for TS but also for other tic disorders and related conditions.

As the trial advances, stakeholders will be looking for evidence of efficacy and safety that could support regulatory filings. The company's belief in SCI-110's potential reflects a broader trend toward cannabinoid-based therapies in neurology, but rigorous clinical data are essential to establish its place in treatment paradigms.

The initiation at Yale marks a step forward in the development of SCI-110, bringing hope to patients and clinicians seeking better options for Tourette syndrome.